Products and clinical projects

Drugs on the market:
Eligard®
VeregenTM
(Polyphenon®
E Ointment)

Projects in clinical
development:
EndoTAGTM-1
RhuDex®
Oncolytic viruses (HSV)

Technologies:
EndoTAGTM
Oncolytic viruses (HSV)
Projects in Clinical Development
Product Indication Preclinic/
Research		 Clinical Phase Approval Marketed Peak Sales Potential 1)
(in million €)
  I II III  
 Eligard® 2)  > 100 3)
 VeregenTM (Polyphenon®
 E Ointment)		 Genital Warts  > 200 4)
  Actinic Keratosis 5)  
 
       > 200
 EndoTAG®-1 Pancreatic Cancer      > 200
  Breast Cancer  
 
        > 1000
  Additional solid tumors            > 400
 RhuDex® Rh. Arthritis  
 
        > 1000
 HSV (NV1020) Colon Liver Metastases  
 
        > 150
 HSV (G207) Glioblastoma            > 70
Chance of reaching the market 10-30% 30-60% 60-80% 80-90%
 

1 Mio. € per year, peak sales. MediGene will recieve royalties from sales at products, which are jointly developed or marketed with biotech or pharmaceuticals companies
2 European marketing rights acquired from QLT USA Inc.(formerly Atrix). For legal reasons the indication is not mentioned on the internet (German Law on Drug Advertising)
3 Marketing partnership with Astellas Pharma Ltd.
4 US-Marketing Partnership with Bradley Pharmaceuticals, Inc.
5 Precursors of a specific kind of skin cancer
6 European marketing rights acquired from Collagenex Inc., USA. (now Galderma).